Montgomery County announces $2.8 billion investment for East County's Viva White Oak
MoCo Minute | AstraZeneca opens $300M cell therapy facility in Rockville
In partnership with MCB Real Estate, the project will span 280 acres near the U.S. Food and Drug Administration campus.
Once complete, Viva White Oak is expected to deliver more than 9,000 permanent jobs, nearly 5,000 homes, and 27,000 construction jobs. Plans include commercial, residential, retail, and public spaces, along with new parks, bike lanes, and water and sewer infrastructure.
'At the Viva White Oak property, we have an excellent development team coming to the County with a plan to get shovels in the ground and open up the new chapter in economic development that District 5 residents have been waiting for. I have seen firsthand the high value that MCB places on community engagement and local collaboration, and I look forward to taking the next step to bring this opportunity to fruition,' said Councilmember Kristin Mink.
Officials noted that once the project is complete, it will generate about $62 million in annual county revenue.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
6 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
Yahoo
a day ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
